Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hollie Beck-Noia"'
Autor:
Katherine C. Fuh, David G. Mutch, Matthew A. Powell, Premal H. Thaker, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Hollie Beck-Noia, Peinan Zhao, Lei Guo, Katina Massad, Gregory Opara, Marguerite L. Palisoul, Molly M. Greenwade, Jeanne M. Quinn
Supplementary Tables. S1 - AXL expression and chemoresponse. AXL h-score is significantly higher in chemoresistant tumors. S2 - MVA to predict chemoresistance. High AXL staining is associated with chemoresistance. S3 - Clinical and Pathological Chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a0fbf4f42a0a02bc43bca04d73f952
https://doi.org/10.1158/1535-7163.22510657
https://doi.org/10.1158/1535-7163.22510657
Autor:
Katherine C. Fuh, David G. Mutch, Matthew A. Powell, Premal H. Thaker, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Hollie Beck-Noia, Peinan Zhao, Lei Guo, Katina Massad, Gregory Opara, Marguerite L. Palisoul, Molly M. Greenwade, Jeanne M. Quinn
Ovarian cancer, one of the deadliest malignancies in female cancer patients, is characterized by recurrence and poor response to cytotoxic chemotherapies. Fewer than 30% of patients with resistant disease will respond to additional chemotherapy treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f9d2b2d5b3d3f91750d21e4d665d260
https://doi.org/10.1158/1535-7163.c.6539674
https://doi.org/10.1158/1535-7163.c.6539674
Autor:
Katherine C. Fuh, David G. Mutch, Matthew A. Powell, Premal H. Thaker, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Hollie Beck-Noia, Peinan Zhao, Lei Guo, Katina Massad, Gregory Opara, Marguerite L. Palisoul, Molly M. Greenwade, Jeanne M. Quinn
Supplementary Figures. S1 - AXL and overall survival. High AXL is associated with poor OS. S2 - BGB324 treatment and downstream inhibition. BGB324 treatment inhibits pAXL and downstream activation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed34bdfcf7ac2bdb8206d9c00df92c3
https://doi.org/10.1158/1535-7163.22510660
https://doi.org/10.1158/1535-7163.22510660
Autor:
Katherine Fuh, Hollie Beck-Noia, David G. Mutch, M. Palisoul, Lei Guo, J.M. Quinn, Andrea R. Hagemann, Premal H. Thaker, Peinan Zhao, M. Greenwade, Carolyn K. McCourt, Gregory Opara, Matthew A. Powell, Katina Massad, Ian S. Hagemann
Publikováno v:
Molecular Cancer Therapeutics. 18:389-398
Ovarian cancer, one of the deadliest malignancies in female cancer patients, is characterized by recurrence and poor response to cytotoxic chemotherapies. Fewer than 30% of patients with resistant disease will respond to additional chemotherapy treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d0c02ac35a654e2e3b3a3645b6b1d9
https://doi.org/10.1158/1535-7163.mct-18-0537
https://doi.org/10.1158/1535-7163.mct-18-0537
